Kailera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing a broad portfolio of next-generation therapies for obesity and metabolic disorders. The company's pipeline is built around several differentiated incretin-based programs designed to offer improved efficacy and convenience for patients. Kailera's lead assets include KLR-102, a long-acting GLP-1/GIP/glucagon receptor tri-agonist currently in clinical development, as well as oral small molecule GLP-1 receptor agonists. These programs aim to address the global obesity epidemic by providing potent weight loss solutions and managing comorbid conditions such as type 2 diabetes and cardiovascular disease. Formed with a significant capital commitment and a suite of licensed assets from Jiangsu Hengrui Pharmaceuticals, Kailera is led by a management team with extensive experience in the biotechnology and metabolic sectors. The company is positioned to compete in the rapidly expanding incretin market by leveraging its diverse clinical-stage portfolio and focusing on the next wave of innovation in metabolic health.
We couldn't find any ticker for KLRA. Please check if the ticker was entered correctly—or if it is listed. If not, we don't have any data for that asset at the moment :(
...and much more!